Abstract The risk of atherosclerotic cardiovascular disease (ASCVD) is strongly related to lifetime exposure to low-density lipoprotein (LDL)-cholesterol in longitudinal studies. Lipid-lowering therapy (using statins, ezetimibe and PCSK9 inhibitors) substantially

Abstract Aims Statin intolerance (SI) represents a significant public health problem for which precise estimates of prevalence are needed. Statin intolerance remains an important clinical

https://ilep.eu/wp-content/movies/20221008082604_live7603_2022-10-08-07.47.08.515-UTC.mp4

The 1st ILEP Symposium has come to an end. Finally, we are ready to share the official statistics of this event. Please see the attached

We are pleased to invite you to participate in a free webinar organized by the European Atherosclerosis Society (EAS) together with The Polish Lipid Association,

Inflammation plays a central role in the pathogenesis and clinical manifestations of atherosclerosis. Randomized controlled trials have investigated the potential benefit of colchicine in reducing

Familial hypercholesterolaemia (FH) is a genetic and complex multifactorial lipid disorder, which increases the risk of premature atherosclerosis and coronary artery disease. FH is still

Fig. 1. Direct potential causes of myocarditis. Myocarditis is an inflammatory disease of the myocardium that mostly affects young adults. The disease is commonly caused